[1]BioorganicandMedicinalChemistryLetters,1997,vol.7,p.2223-2228
[1]BioorganicandMedicinalChemistryLetters,1997,vol.7,p.2223-2228
[2]Patent:US2012/136015,2012,A1
[3]OrganicProcessResearchandDevelopment,2002,vol.6,p.120-124
[4]Patent:CN104193687,2017,B
[1]Patent:US2009/156811,2009,A1.Locationinpatent:Page/Pagecolumn4-5
[2]Patent:EP2072503,2009,A2.Locationinpatent:Page/Pagecolumn7
[3]Patent:US2009/156811,2009,A1.Locationinpatent:Page/Pagecolumn5
[4]Patent:WO2009/112954,2009,A2.Locationinpatent:Example5
[1]Patent:WO2010/15623,2010,A1.Locationinpatent:Page/Pagecolumn15
[1]Patent:WO2011/24056,2011,A2
[2]Patent:WO2011/24056,2011,A2
[3]Patent:US2012/136015,2012,A1
Title: Dhillon S, et al. Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension. Am J Cardiovasc Drugs. 2009;9(5):331-50.
Title: Akamata K, et al. Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1. Arthritis Res Ther. 2014 Apr 3;16(2):R86.
Title: Iglarz M, et al. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension. Life Sci. 2014 Nov 24;118(2):333-9.
Title: Son GY, et al. Endothelin Regulates Porphyromonas gingivalis-Induced Production of Inflammatory Cytokines. PLoS One. 2016 Dec 28;11(12):e0167713.
